Dosing of CD38-binding fusion protein

Disclosed herein are methods of treating cancer (e.g., hematologic or solid tumor) with a CD38-binding fusion protein, and optionally in combination with an immune checkpoint inhibitor (e.g., a PD-1 inhibitor such as pembrolizumab).

Saved in:

Bibliographic Details
Main Authors	COLLINS, SABRINA, WANG, SHINING, LI, SHUANG WU (CHERYL), RIBAS, IGNACIO GARCIA, YANG, HUI, GUPTA, NEERAJ, CHEN, TIAN, LARSON, RYAN, SURYANARAYAN, KAVERI, LIU, YU-YIN, PAROT, XAVIER
Format	Patent
Language	Chinese English
Published	16.03.2024
Subjects	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online Access	Get full text

Cover

Loading…

More Information
Summary:	Disclosed herein are methods of treating cancer (e.g., hematologic or solid tumor) with a CD38-binding fusion protein, and optionally in combination with an immune checkpoint inhibitor (e.g., a PD-1 inhibitor such as pembrolizumab).
Bibliography:	Application Number: TW202312119729